{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039777","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.679630+00:00","generated_at":"2026-06-12T02:11:43.292017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxcyte reports Q2 net loss $68.3M, cash $1.44B, VAX-24 infant Phase 2 advanced to Stage 2","bullets":["Cash $1.44B as of June 30, includes $545M net from April public offering.","Net loss $68.3M for Q2 2023 vs $48.5M in Q2 2022; R&D expenses $72.7M.","VAX-24 infant Phase 2 advanced to final stage; topline primary data expected by 2025.","VAX-24 adult Phase 2 positive; Phase 3 topline data expected 2025; VAX-31 IND clearance expected Q4 2023.","Board member Michael Kamarck passed away in July 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039777","json":"https://secwatch.observer/filing/0000950170-23-039777.json","markdown":"https://secwatch.observer/filing/0000950170-23-039777.md","text":"https://secwatch.observer/filing/0000950170-23-039777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/0000950170-23-039777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/pcvx-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:11:43.292017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46d8fb12662e556c696db2c07d25b3fab35df37e","claim":"Vaxcyte, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/0000950170-23-039777-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}